Efficacy of up to 4 years of tralokinumab in adults with moderate‐to‐severe atopic dermatitis
Bibliographic record
Abstract
BACKGROUND: Atopic dermatitis (AD) is a relapsing and remitting skin disease often requiring long-term treatment. Tralokinumab, a monoclonal antibody specifically neutralizing interleukin-13, is approved for moderate-to-severe AD treatment in multiple countries. OBJECTIVES: Assess long-term efficacy of tralokinumab in adults with moderate-to-severe AD treated for up to 4 years. METHODS: This post hoc interim analysis included the subgroup of patients (n = 347) who completed 52 weeks of tralokinumab in the Phase 3 ECZTRA 1 or ECZTRA 2 (NCT03131648/NCT03160885) trials and subsequently enrolled in the open-label extension trial ECZTEND (NCT03587805; receiving tralokinumab plus optional topical corticosteroids/calcineurin inhibitors [TCS/TCI]) ≥152 weeks prior to data cut-off (30-April-2022). RESULTS: At ECZTEND Week 152, 52.6% (95% CI 45.2; 59.8) of patients achieved Investigator's Global Assessment 0/1 (clear or almost clear skin) and 84.5% (95% CI 78.4; 89.1) achieved ≥75% improvement in Eczema Area and Severity Index (EASI) from parent trial baseline; additionally, 84.5% (95% CI 78.4; 89.1), 68.0% (95% CI 60.8; 74.5) and 79.0% (95% CI 72.1; 84.6) reached EASI ≤7 (no-to-mild disease), Worst Weekly Pruritus Numeric Rating Scale ≤4 (no-to-mild itch) and Dermatology Life Quality Index ≤5 (no-to-small effect on quality of life), respectively. Responses were stable over time, with 71.4% (95% CI 66.3; 76.0) of patients maintaining EASI ≤7 at ≥80% of days between Week 16 and 152 in ECZTEND. During ECZTEND, 28.5% of patients discontinued: 7.5% due to lack of efficacy and 5.8% due to adverse events (AEs). The most frequently reported AEs in ECZTEND were consistent with the known safety profile of tralokinumab, including nasopharyngitis (IR = 13.6), upper respiratory tract infection (IR = 4.4) and conjunctivitis (IR = 2.3). CONCLUSIONS: These data suggest that tralokinumab plus optional TCS/TCI provides long-term stable disease control, equivalent to no-to-mild disease, in a subgroup of adults with moderate-to-severe AD who completed 1 year of treatment in parent trials and up to 3 years in ECZTEND.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.002 | 0.002 |
| Meta-epidemiology (narrow) | 0.001 | 0.000 |
| Meta-epidemiology (broad) | 0.002 | 0.003 |
| Bibliometrics | 0.000 | 0.000 |
| Science and technology studies | 0.001 | 0.000 |
| Scholarly communication | 0.001 | 0.001 |
| Open science | 0.000 | 0.001 |
| Research integrity | 0.001 | 0.002 |
| Insufficient payload (model declined to judge) | 0.003 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".